120 results
Page 2 of 6
6-K
EX-99.1
ygz764e6
28 Jun 22
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
4:13pm
6-K
EX-99.1
7h8ff efaxfwsd0
17 Jun 22
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:05am
6-K
oz2230 916hje4
27 May 22
ObsEva Announces Corporate Updates
4:56pm
6-K
EX-99.1
uqr4bs
27 May 22
ObsEva Announces Corporate Updates
4:56pm
6-K
EX-99.3
8aoq45m8q
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
0x9heu27 atikxe
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.1
1u9k7f880u 650uipvl
2 May 22
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
7:00am
6-K
EX-99.1
r04xjlqj
25 Apr 22
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH
7:00am
6-K
EX-99.1
po73ka
22 Mar 22
Current report (foreign)
7:28am
6-K
EX-99.1
2mactsxe7q88y
10 Mar 22
ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
7:11am
6-K
EX-99.1
xbnvbheuxyom99
10 Feb 22
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
4:27pm
6-K
EX-99.1
dcmaon s6dol
4 Feb 22
ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral
4:37pm
6-K
EX-99.1
f1r3iyj de
1 Feb 22
ObsEva Appoints Katja Buhrer as Chief Strategy Officer
6:05am
6-K
vw2w11miry lpyk
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
6-K
EX-99.3
qwfa7bya0bsfrifgy98j
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
6-K
EX-99.1
c95ku97f0iwg 46
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm